



Derma
Consult
GmbH

Gesellschaft zur Prüfung von
Dermatika

DC Brunnenstraße 61 53347 Alfter Germany

Phone: +49 - (0)2222 / 9108 - 10
Fax: +49 - (0)2222 / 9108 - 40
E-mail: info@dermaconsult.com
Web: www.dermaconsult.com
Date: 19.10.2018

Expertise

Examination of the Product

“Rezilin® Basilikum-Extrakt Haarkur Bioqualität”

F-442 Charge: NK-9818-393-02

Concentration: undiluted

by Human Patch Test (Cosmetic Trial)

Sponsor

evommerce GmbH
Speicherstrasse 20
60327 Frankfurt am Main
Germany

Performing Laboratory

Derma Consult GmbH
Brunnenstr. 61
53347 Alfter
Germany

Study Details

Type of study.....: Determination of irritating effects to the skin with an occlusive patch test.
Study Period.....: October 2018
Study Director.....: Dr. med. H. Prieur
Test subjects.....: 50 (19-72 years; sex distribution non-standardized)
28 normal healthy, 3 eczema, 4 allergy and 15 subjects with sensitive skin
Test site.....: Back
Concentration.....: Undiluted
Controls.....: SDS (1% in water), water

Summary Results

All participants completed the study. Under the test conditions, SDS (1% in water) caused positive reactions in 16 subjects. The negative control water showed no reactions. None of the subjects showed any reaction to the test product. On the basis of the test results and under the test conditions, the product

“Rezilin® Basilikum-Extrakt Haarkur Bioqualität“

is to be classified as 'harmless' as regards the possibility of skin irritation.

Signature:

Dr. med. H. Prieur
Dermatologist - Allergist

Signature:

Dr. J. Nissen
Pharmacist - M.D.R.A.

Methodology

Introduction

The epicutaneous patch test allows us to assess the primary skin irritation potential of cosmetic-finished products and raw materials.

Description

All the work described in this expertise was conducted considering the guidelines by COLIPA (Walker A.P. et al: Test Guidelines for Assessment of Skin Compatibility of Cosmetic Finished Products in Man. Food and Chemical Toxicology 34, 1996, 651-660; COSMETICS EUROPE: Product test guidelines for the assessment of human skin compatibility 1997).

Because it was a study with humans, it was carried out taking into account the principle requirements of the Declaration of Helsinki (1964) and subsequent revisions.

Experiments were carried out on 50 volunteers (28 normal healthy subjects, 3 eczema patients, 4 allergy patients, 15 subjects with sensitive skin) between the ages of 19 to 72. Sex distribution was not standardized. The volunteers were clearly informed, verbally and in writing, regarding the nature of the study, the timetable, constraints and possible risks. They gave their written informed consent before participating in the study.

Participants could withdraw from the study at any time without giving reason. During the test period, the subjects refrained from using other substances on the test areas.

Inclusion criteria

- informed volunteers
- age \geq 18 years

Exclusion criteria

- pregnant or lactating women
- blemishes or marks (tattoos, sunburn) which interfere with scoring
- any skin disease that may interfere with the aim of the study

Procedure

The product was applied in a concentration as outlined above in square test-chambers (allergEAZE[®] clear Patch Test Chambers; SmartPractice[®], Phoenix, AZ) to the backs of the panellists for a period of 48 hours. Proper adherence of the test patches was assured by the inclusion of sodium dodecyl sulphate (SDS) in one concentration (1%) as positive control. Water was used as a negative control.

The treatment sites were assessed for the presence of irritation by a trained evaluator using a 5 point visual scoring scale at 48 h (30 min after patch removal) and 72 h after patch application.

Scoring scale

| | |
|-----------------|---|
| <u>Erythema</u> | 0: no E., 1: slight E., 2: significant E., 3: pronounced E., 4: strong E. |
| <u>Fissure</u> | 0: no F., 1: minimal F., 2: significantly perceptible F., 3: pronounced F., 4: ulceration |
| <u>Scaling</u> | 0: no Sc., 1: minimal Sc., 2: moderate Sc., 3: significant Sc., 4: closed scale crust |

Results

The test results outlining the data for erythema, scaling and fissure formation on a per subject base for the test product are attached in tabulated form.

Literature

Magnus Lindberg and Mihaly Matura:
“Patch Testing” in
J. D. Johansen, P.J. Frosch, J.-P. Lepoittevin (Eds.),
Contact Dermatitis 5th Edition
Springer-Verlag, Berlin Heidelberg, Germany (2011), pp. 439-464

J-M. Lachapelle, H. I. Maibach:
“Patch Testing and Prick Testing - A practical Guide
Official Publication of the ICDRG“
Third Edition
Springer-Verlag, Berlin Heidelberg, Germany (2012)

Appendix: test protocol

| No. | Type | after 48 h | | | after 72 h | | |
|------------|------|------------|-----|-----|------------|-----|-----|
| | | E | F | S | E | F | S |
| 1 | A | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | A | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 6 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 7 | E | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 9 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 10 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 11 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 12 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 13 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 14 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 15 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 16 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 17 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 | A | 0 | 0 | 0 | 0 | 0 | 0 |
| 19 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 20 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 21 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 22 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 23 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 24 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 25 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 26 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 27 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 28 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 29 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 30 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 31 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 32 | A | 0 | 0 | 0 | 0 | 0 | 0 |
| 33 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 34 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 35 | E | 0 | 0 | 0 | 0 | 0 | 0 |
| 36 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 37 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 38 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 39 | E | 0 | 0 | 0 | 0 | 0 | 0 |
| 40 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 41 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 42 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 43 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 44 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 45 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 46 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 47 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 48 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 49 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 50 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| SUM | | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |

Erythema (E): no E.: 0, slight E.: 1, clear E.: 2, severe E.: 3, very severe E.: 4
 Fissures (F): no F.: 0, minimal F.: 1, clearly visible F.: 2, distinct F.: 3, ulceration: 4
 Scales (S): no S.: 0, minimal S.: 1, clearly visible S.: 2, moderate S.: 3, distinct S.: 4

S: subjects with sensitive skin
 E: patients with eczema
 A: patients with allergy

| No. | Type | after 48 h | | | after 72 h | | |
|-----|------|------------|-----|-----|------------|-----|-----|
| | | E | F | S | E | F | S |
| 1 | A | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | A | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 6 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 7 | E | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 9 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 10 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 11 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 12 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 13 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 14 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 15 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 16 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 17 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 | A | 0 | 0 | 0 | 0 | 0 | 0 |
| 19 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 20 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 21 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 22 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 23 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 24 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 25 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 26 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 27 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 28 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 29 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 30 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 31 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 32 | A | 0 | 0 | 0 | 0 | 0 | 0 |
| 33 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 34 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 35 | E | 0 | 0 | 0 | 0 | 0 | 0 |
| 36 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 37 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 38 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 39 | E | 0 | 0 | 0 | 0 | 0 | 0 |
| 40 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 41 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 42 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 43 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 44 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 45 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 46 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 47 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 48 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 49 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 50 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| SUM | | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |

Erythema (E): no E.: 0, slight E.: 1, clear E.: 2, severe E.: 3, very severe E.: 4
 Fissures (F): no F.: 0, minimal F.: 1, clearly visible F.: 2, distinct F.: 3, ulceration: 4
 Scales (S): no S.: 0, minimal S.: 1, clearly visible S.: 2, moderate S.: 3, distinct S.: 4

S: subjects with sensitive skin
 E: patients with eczema
 A: patients with allergy

| No. | Type | after 48 h | | | after 72 h | | |
|-----|------|------------|-----|------|------------|-----|-----|
| | | E | F | S | E | F | S |
| 1 | A | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | A | 1 | 0 | 0 | 0 | 0 | 0 |
| 3 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | S | 1 | 0 | 1 | 1 | 0 | 0 |
| 6 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 7 | E | 1 | 0 | 0 | 1 | 0 | 0 |
| 8 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 9 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 10 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 11 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 12 | S | 1 | 0 | 0 | 0 | 0 | 0 |
| 13 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 14 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 15 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 16 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 17 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 | A | 1 | 0 | 0 | 0 | 0 | 0 |
| 19 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 20 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 21 | | 1 | 0 | 0 | 1 | 0 | 0 |
| 22 | S | 2 | 0 | 1 | 1 | 0 | 1 |
| 23 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 24 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 25 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 26 | S | 1 | 0 | 0 | 1 | 0 | 0 |
| 27 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 28 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 29 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 30 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 31 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 32 | A | 2 | 0 | 1 | 2 | 0 | 1 |
| 33 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 34 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 35 | E | 1 | 0 | 1 | 1 | 0 | 1 |
| 36 | S | 0 | 0 | 0 | 0 | 0 | 0 |
| 37 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 38 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 39 | E | 1 | 0 | 0 | 1 | 0 | 0 |
| 40 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 41 | S | 2 | 0 | 2 | 2 | 0 | 2 |
| 42 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 43 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 44 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 45 | S | 1 | 0 | 0 | 1 | 0 | 0 |
| 46 | S | 1 | 0 | 0 | 0 | 0 | 0 |
| 47 | S | 1 | 0 | 0 | 0 | 0 | 0 |
| 48 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 49 | | 0 | 0 | 0 | 0 | 0 | 0 |
| 50 | S | 1 | 0 | 0 | 1 | 0 | 0 |
| SUM | | 0,38 | 0,0 | 0,12 | 0,26 | 0,0 | 0,1 |

Erythema (E): no E.: 0, slight E.: 1, clear E.: 2, severe E.: 3, very severe E.: 4
 Fissures (F): no F.: 0, minimal F.: 1, clearly visible F.: 2, distinct F.: 3, ulceration: 4
 Scales (S): no S.: 0, minimal S.: 1, clearly visible S.: 2, moderate S.: 3, distinct S.: 4

S: subjects with sensitive skin
 E: patients with eczema
 A: patients with allergy